Inmed Pharmaceuticals Inc (IMLFF) 0.1275 $IMLFF
Post# of 273256
Posted On: 10/11/2015 6:52:31 AM
Inmed Pharmaceuticals Inc (IMLFF) 0.1275 $IMLFF
InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).
InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
ABUS: 6.12 (-0.14), TKMR: 10.83 (+0.58)
InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling.
InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS.
Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 4.18 (+0.31), SHPG: 200.90 (-1.85), GSK: 40.22 (+0.06)
Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 200.90 (-1.85), GSK: 40.22 (+0.06)
InMed Pharmaceuticals Inc. (IMLFF) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:01AM CDT
InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF), a clinical stage biopharmaceutical company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline
Marketwired - Wed Jun 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic obstructive pulmonary disease (COPD). Initial drug discovery and preclinical development is currently underway in collaboration with members of the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia.
InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)
PR Newswire - Tue May 26, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" (CSE: IN; OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO" relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed.
InMed Pharmaceuticals Files Provisional Patent Application for Treating Eye Disease - Video News Alert on InvestmentPitch.com
Newsfile Corp - Wed May 13, 10:32AM CDT
full story)
InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
Marketwired - Tue May 12, 11:45AM CDT
InMed Pharmaceuticals Inc. ("InMed" or the "Company" (CSE: IN)(OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO" relating to the treatment of eye diseases.
CARERS Act Likely to Intensify Awareness for DUI Laws and Need for Marijuana Breathalyzer
ACCESSWIRE - Wed May 06, 7:01AM CDT
WHITFISH, MT / ACCESSWIRE / May 6, 2015 / The marijuana industry received some substantial news in March with bi-partisan support in both chambers of Congress that would facilitate growth for the industry by loosening federal marijuana laws. Rep. Steve Cohen (D-TN) with co-sponsor Rep. Don Young (R-AK) filed the House version of the CARERS Act (short for Compassionate Access, Research Expansion, and Respect States) and six additional House members co-sponsoring the bill have now joined them. The Senate version, filed by Senators Cory Booker (D-NJ), Rand Paul (R-KY), and Kirsten Gillibrand (D-NY) earlier in the month has added two additional senators as co-sponsors. The CARERS Act aims to resolve several problematic regulations with marijuana, including allowing interstate commerce, opening the banking system to marijuana dispensaries, permitting the Veterans Administration to recommend medical marijuana to vets, rescheduling marijuana to Schedule 2, allowing states to legalize marijuana for medical use without federal interference and eliminate barriers to medical marijuana research. If passed into law, it will benefit a wide array of marijuana companies, including cannabinoid-based drug developers like GW Pharmaceuticals (NASDAQ: GWPH), Insys Therapeutics (NASDAQ: INSY) and InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN).
INSY: 25.65 (+0.64), GWPH: 87.75 (+0.45), ABBV: 55.64 (-0.40)
InMed Appoints Paul Brennan as President & Chief Executive Officer
Marketwired - Thu Sep 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors. InMed Commences Development of Proprietary Drug Delivery System
Marketwired - Wed Sep 02, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015). InMed Appoints Paul Brennan to the Board of Directors
Marketwired - Tue Aug 25, 4:00AM CDT
InMed Pharmaceuticals Inc. ("InMed" or "the Company"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States. ABUS: 6.12 (-0.14), TKMR: 10.83 (+0.58)
InMed Pharmaceuticals Announces Progress in Orofacial Pain Program
Marketwired - Thu Aug 20, 7:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announces today the successful completion and validation of preclinical pain modelling. InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)
Marketwired - Thu Aug 06, 4:01AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS. Epidermolysis Bullosa - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxnlsl/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Fibrocell Science, Inc. - GlaxoSmithKline plc - InMed Pharmaceuticals Inc. - RegeneRx Biopharmaceuticals, Inc. - Scioderm, Inc. - Shire Plc - TWi Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/jx...dermolysis
FCSC: 4.18 (+0.31), SHPG: 200.90 (-1.85), GSK: 40.22 (+0.06)
Epidermolysis Bullosa Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jun 25, 8:31PM CDT
The report "Epidermolysis Bullosa - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Epidermolysis Bullosa. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/epidermolysi...eport.html .
SHPG: 200.90 (-1.85), GSK: 40.22 (+0.06)
InMed Pharmaceuticals Inc. (IMLFF) to Present at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on June 10
GlobeNewswire - Thu Jun 04, 7:01AM CDT
InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF), a clinical stage biopharmaceutical company, will be presenting at the Small-Cap Stars Spring Conference 2015 at Convene in Times Square New York on Wednesday, June 10. The event is a gathering of the brightest emerging growth small-cap and pre-IPO companies to present and network with an exclusive group of top-level institutional investors.
InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline
Marketwired - Wed Jun 03, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN)(OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, announced it has initiated a program to identify and evaluate cannabinoid compounds for the treatment of chronic obstructive pulmonary disease (COPD). Initial drug discovery and preclinical development is currently underway in collaboration with members of the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia. InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)
PR Newswire - Tue May 26, 5:00AM CDT
InMed Pharmaceuticals Inc. ("InMed"
(CSE: IN; OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO" relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed. InMed Pharmaceuticals Files Provisional Patent Application for Treating Eye Disease - Video News Alert on InvestmentPitch.com
Newsfile Corp - Wed May 13, 10:32AM CDT
full story)
InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases
Marketwired - Tue May 12, 11:45AM CDT
InMed Pharmaceuticals Inc. ("InMed" or the "Company"
(CSE: IN)(OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO" relating to the treatment of eye diseases. CARERS Act Likely to Intensify Awareness for DUI Laws and Need for Marijuana Breathalyzer
ACCESSWIRE - Wed May 06, 7:01AM CDT
WHITFISH, MT / ACCESSWIRE / May 6, 2015 / The marijuana industry received some substantial news in March with bi-partisan support in both chambers of Congress that would facilitate growth for the industry by loosening federal marijuana laws. Rep. Steve Cohen (D-TN) with co-sponsor Rep. Don Young (R-AK) filed the House version of the CARERS Act (short for Compassionate Access, Research Expansion, and Respect States) and six additional House members co-sponsoring the bill have now joined them. The Senate version, filed by Senators Cory Booker (D-NJ), Rand Paul (R-KY), and Kirsten Gillibrand (D-NY) earlier in the month has added two additional senators as co-sponsors. The CARERS Act aims to resolve several problematic regulations with marijuana, including allowing interstate commerce, opening the banking system to marijuana dispensaries, permitting the Veterans Administration to recommend medical marijuana to vets, rescheduling marijuana to Schedule 2, allowing states to legalize marijuana for medical use without federal interference and eliminate barriers to medical marijuana research. If passed into law, it will benefit a wide array of marijuana companies, including cannabinoid-based drug developers like GW Pharmaceuticals (NASDAQ: GWPH), Insys Therapeutics (NASDAQ: INSY) and InMed Pharmaceuticals (OTCQB: IMLFF) (CSE: IN).
INSY: 25.65 (+0.64), GWPH: 87.75 (+0.45), ABBV: 55.64 (-0.40)
(0)
(0)Scroll down for more posts ▼